Results 11 to 20 of about 214,341 (267)
Focus on Nivolumab in NSCLC [PDF]
Frontiers in Medicine, 2016 Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach to treating NSCLC using immunotherapy still has unsolved questions and challenging issues.
Cortinovis D. L. +4 more
openaire +3 more sources
Lung Cancer Management, 2016 In the era of high-throughput molecular screening and personalized medicine, difficulty in determining whether cancer mutations are truly 'actionable' remains a gray zone in NSCLC. The most important prerequisite to perform such investigations is the tumor tissue retrieval via biopsy at diagnosis and after occurrence of resistance.
Trombetta, D. +3 more
openaire +2 more sources
Frontiers in Oncology, 2012 The phosphatidylinositol 3-kinases (PI3Ks) are members of a family of intracellular lipid kinases that phosphorylate the 3'-hydroxyl group of phosphatidylinositol and phosphoinositides. PI3K regulate signaling pathways for neoplasia, including cell proliferation, adhesion, survival, and motility.
Martinez-Martí, Alex, Felip, Enriqueta
openaire +3 more sources
Cancers, 2023 Non-small cell lung cancer (NSCLC) is still one of the leading causes of death worldwide. This is mostly because the majority of lung cancers are discovered in advanced stages. In the era of conventional chemotherapy, the prognosis of advanced NSCLC was grim. Important results have been reported in thoracic oncology since the discovery of new molecular
Cannone, Giorgio +7 more
openaire +3 more sources
Immunotherapeutic Advances for NSCLC
Biologics: Targets and Therapy, 2021 Immunotherapy with antibodies against PD-1 or PD-L1, either alone or in combination with chemotherapy, has revolutionized treatment paradigms of non-small cell lung cancer (NSCLC) patients without oncogenic driver alterations. These agents, namely immune checkpoint inhibitors (ICIs), have also widely demonstrated a remarkable efficacy in locally ...
Massafra, Marco +8 more
openaire +5 more sources
Angiogenesis Inhibitors in NSCLC [PDF]
International Journal of Molecular Sciences, 2017 Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy ...
Manzo, Anna +10 more
openaire +2 more sources
The efficacy of durvalumab in locally advanced lung carcinoma [PDF]
Archive of OncologyBackground: The integration of durvalumab, an immune checkpoint inhibitor, as consolidation therapy following platinum-based chemoradiotherapy has redefined the standard of care for patients with stage III, unresectable non-small cell lung cancer (NSCLC)
Knežević Isidora +3 more
doaj +1 more source
Cancer Management and Research, 2023 Wei-Fan Ou,1 Pei-Ya Liao,1 Yu-Wei Hsu,2,3 Yen-Hsiang Huang,1,4– 6 Kuo-Hsuan Hsu,6,7 Jeng-Sen Tseng,1,4– 6,8 Gee-Chen Chang,4,9– 11 Tsung-Ying Yang1,6,12 1Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital ...
Ou WF +7 more
doaj
Cancer Research, Statistics, and Treatment, 2019 Non-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic chemotherapy, which resulted in a median overall survival of 7.9 months.
Akhil Rajendra +5 more
doaj +1 more source
Non-small-cell lung cancer metastasis to unusual sites: A retrospective case series
Cancer Research, Statistics, and Treatment, 2021 Background: The majority of all lung cancers are non-small-cell lung cancers (NSCLCs). They usually spread to the pleura, brain, adrenal gland, lungs, liver, and bones.
Sandip Ganguly +6 more
doaj +1 more source